Leng W, et al. - Researchers used data of China Acute Myocardial Infarction Registry to analyze the trends of contemporary medical and invasive management of patients with non-ST-segment elevation myocardial infarction (NSTEMI) across China. Of 10,266 NSTEMI patients enrolled between January 2013 and November 2016, 92.9% were prescribed dual antiplatelet therapy and 92.1% were treated with statins. Of these, 45.6% underwent coronary angiography (CAG) and 40.9% had an index revascularization. The chances of receiving CAG or revascularization were less likely in female, older, or higher risk patients. At the provincial-l, prefectural-, and county-level hospitals, the rates of CAG were 67.9%, 46.2%, and 12.1%, respectively. The overall in-hospital major adverse cardio-cerebral events (MACCE) and the median length of stay were 6.7% and 10 (6) days, respectively. Attenuation of in-hospital MACCE was reported in relation to revascularization, irrespective of risk and age. In China, invasive management was underused and profoundly deferred among patients with NSTEMI. Findings revealed a risk-treatment paradox, procedure deferral, and medical resources distribution imbalance, which may all represent opportunities for improvement.